- Home
- ALF vs AKBA Comparison
ALF vs AKBA Comparison
Compare ALF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- AKBA
- Stock Information
- Founded
- ALF 2024
- AKBA 2007
- Country
- ALF United States
- AKBA United States
- Employees
- ALF N/A
- AKBA N/A
- Industry
- ALF
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- ALF
- AKBA Health Care
- Exchange
- ALF NYSE
- AKBA Nasdaq
- Market Cap
- ALF 360.5M
- AKBA 336.2M
- IPO Year
- ALF 2024
- AKBA 2014
- Fundamental
- Price
- ALF $10.04
- AKBA $1.88
- Analyst Decision
- ALF
- AKBA Strong Buy
- Analyst Count
- ALF 0
- AKBA 2
- Target Price
- ALF N/A
- AKBA $5.75
- AVG Volume (30 Days)
- ALF 38.9K
- AKBA 2.4M
- Earning Date
- ALF 01-01-0001
- AKBA 11-07-2024
- Dividend Yield
- ALF N/A
- AKBA N/A
- EPS Growth
- ALF N/A
- AKBA N/A
- EPS
- ALF N/A
- AKBA N/A
- Revenue
- ALF N/A
- AKBA $169,879,000.00
- Revenue This Year
- ALF N/A
- AKBA N/A
- Revenue Next Year
- ALF N/A
- AKBA $6.13
- P/E Ratio
- ALF N/A
- AKBA N/A
- Revenue Growth
- ALF N/A
- AKBA N/A
- 52 Week Low
- ALF $9.96
- AKBA $0.80
- 52 Week High
- ALF $10.25
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- AKBA 61.05
- Support Level
- ALF N/A
- AKBA $1.75
- Resistance Level
- ALF N/A
- AKBA $2.02
- Average True Range (ATR)
- ALF 0.00
- AKBA 0.11
- MACD
- ALF 0.00
- AKBA -0.02
- Stochastic Oscillator
- ALF 0.00
- AKBA 60.00
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.